Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Digestive System Diseases

Gland and Hormone Related Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma, Non-Small-Cell Lung

Carcinoma

Colorectal Neoplasms

Pancreatic Neoplasms

Ovarian Neoplasms

Endometrial Neoplasms

Biliary Tract Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Endocrine Gland Neoplasms

Pancreatic Diseases

Endocrine System Diseases

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Gonadal Disorders

Uterine Neoplasms

Uterine Diseases

Biliary Tract Diseases

Pancreatic Cancer

Ovarian Cancer

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Carboplatin

Pemetrexed

Pembrolizumab

Cetuximab

Cisplatin

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Folinic Acid

Folate

Vitamin B9

LY3537982 administered orally either alone or with another investigational agent.

LY3537982 administered orally either alone or with another investigational agent

LY3537982

Patient Advocacy

Melinda Willard, PhD

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.

This is an open-label, multicenter Phase 1/2 study to evaluate safety, tolerability, and preliminary efficacy of oral LY3537982 in patients with KRAS G12C-mutant solid tumors.

This study will be conducted in 4 parts: Phase 1a dose escalation, Phase 1b dose expansion, Phase 1b dose optimization, and Phase 2. KRAS G12C mutations will be identified through standard of care testing.

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Measured by the number of patients with dose-limiting toxicities (DLTs)

Loxo Oncology, Inc.

Merck Sharp & Dohme LLC

Eli Lilly and Company

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)	NCT04956640	Carcinoma, Non-... Colorectal Neop... Endometrial Neo... Ovarian Neoplas... Pancreatic Neop... Biliary Tract N...	LY3537982 Pembrolizumab Cetuximab Pemetrexed Cisplatin Carboplatin	18 Years -	Eli Lilly and Company
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)	NCT04956640	Carcinoma, Non-... Colorectal Neop... Endometrial Neo... Ovarian Neoplas... Pancreatic Neop... Biliary Tract N...	LY3537982 Pembrolizumab Cetuximab Pemetrexed Cisplatin Carboplatin	18 Years -	Eli Lilly and Company
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)	NCT04956640	Carcinoma, Non-... Colorectal Neop... Endometrial Neo... Ovarian Neoplas... Pancreatic Neop... Biliary Tract N...	LY3537982 Pembrolizumab Cetuximab Pemetrexed Cisplatin Carboplatin	18 Years -	Eli Lilly and Company

Spots Global Cancer Trial Database for 1l

Every month we try and update this database with for 1l cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for 1l

Every month we try and update this database with for 1l cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for 1l cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.